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To the Editor:
This issue’s focus on women and cardiovascular medicine is
timely and critically important. Recently published studies
have underscored, yet again, that cardiovascular disease
research must more effectively and aggressively target
women if it is to produce results that lead to improved
prevention and early detection, accurate diagnosis, and
proper treatment for women.
Specifically, one study found that women have been
underrepresented in NIH-supported cardiovascular random-
ized controlled trials conducted in the past 10 years, despite a
1993 federal law requiring clinical trials to include a
significant proportion of women [1]. Possible reasons for
this failure are varied, ranging from a lack of information
about the availability of clinical trials by women patients and
their healthcare providers to study designs that exclude
women heart patients due to their medical conditions,
medications, or history. Pragmatic concerns by women
patients about how participation in a clinical trial will affect
their health insurance coverage and the logistical difficulties
of transportation and childcare also have an adverse effect on
participation rates [2]. The impact of failing to overcome
these barriers and significantly increasing the number of
women in clinical trials has contributed to a substantial
deficit of gender-based knowledge about everything from the
“typical” heart attack symptoms in women to the risks and
benefits of commonly used diagnostic tests and therapies [3].
Exacerbating this problem are the serious lapses in the U.S.
Food and Drug Administration’s enforcement of its own rule
requiring new drug applicants to submit data by sex, age
group, and race. Far too many applicants fail to comply,
resulting in sorely inconclusive evidence of gender-specific
disease indicators and inadequate guidelines for the clinical
treatment of women [4].
Another new study reveals how this knowledge deficit
contributes to persistent disparities in the care women heart
patients receive as compared to men. The study shows that
women experiencing a major cardiac event are 50% more
likely than men to be delayed by emergency medical
services (EMS) from reaching the hospital and receiving
crucial treatment [5].
The study authors suggest that these treatment delays may
be due to women’s cardiac symptoms differing from men’s
and that both women patients and EMS personnel do not
recognize the health event as cardiac-related. Another study,
published in 2009, showed that women with acute coronary
syndrome were less likely than men to undergo cardiac
catheterization and other therapies, receive beta-blockers,
statins, and other medications, or be discharged with
evidence-based cardiac therapies [6]. The reasons for these
disparities in care are not insurmountable. Conducting
research that accurately reflects the epidemiology of the
disease in women, improving healthcare provider education,
and engaging more informed and empowered women
patients could translate into improved care outcomes,
reduced hospital stays, and lives saved.
As the nation’s only patient-centered advocacy organi-
zation for women with heart disease, WomenHeart is
committed to meeting these challenges in order to ensure
that all women live longer, healthier lives. Community
education, patient support, and advocacy are integral to our
organization’s efforts. We depend heavily on a corps of 400
WomenHeart Champion volunteers, all heart disease
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Mayo Clinic to lead community-based, public education
forums and discussions about cardiovascular health, lead
local support groups across the country, and moderate
online support programs to help women living with heart
disease connect with and support each other. Together with
our outreach efforts and active website, www.womenheart.
org, we are working to inform all women about heart
disease, empower them to reduce their risks, emphasize the
importance of research by sharing latest findings, and urge
more women to participate in clinical trials.
WomenHeart is also a chief advocate for increased
research and prevention funding and policies that will
better address the needs of women with heart disease. The
cornerstone of our advocacy efforts is the HEART (Heart
disease Education, Analysis, Research, and Treatment) for
Women Act, reintroduced February 2009 in the 111th
Congress. This legislation takes a multi-pronged approach
to improve the prevention, diagnosis, and treatment of heart
disease and stroke by authorizing grants to educate health-
care professionals about the prevalence and unique aspects
of cardiovascular disease in women, requiring that federally
reported healthcare data be stratified by gender, race, and
ethnicity, and by improving and expanding screening for
low-income women at risk for heart disease and stroke.
This legislation provides common sense solutions that will
help improve the care—and possibly save the lives—of
millions of women.
The death rate for heart disease in men has declined by
17.5% over the last 25 years, while the rate for women
declined by only 1.5% [7]. The heart disease rate for
women ages 35 to 44 actually rose from 1997 to 2002 [7].
Here, the evidence is clear—we are losing ground in the
fight against women’s heart disease. The action steps we
must take, however, are equally clear and WomenHeart is
eager to partner with the translational research community
to achieve them.
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